Stocks Comparison
Bio-Rad Laboratories vs 10x Genomics: revenue, profit, margins and growth compared
Bio-Rad Laboratories brought in $2.6B of revenue in fiscal 2025, 10x Genomics $642.8M in fiscal 2025. Revenue changed by +0.7% at Bio-Rad Laboratories and +5.2% at 10x Genomics on the year before, so 10x Genomics grew faster. Bio-Rad Laboratories kept 29.4% of its revenue as net profit, 10x Genomics -6.8%. Free cash flow was $374.6M at Bio-Rad Laboratories and $130.1M at 10x Genomics.
Side by side, latest fiscal year
| BIO | TXG | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $2.6B | $642.8M |
| Revenue growth | +0.7% | +5.2% |
| Net income | $759.9M | -$43.5M |
| Net margin | 29.4% | -6.8% |
| Free cash flow | $374.6M | $130.1M |
| Free cash flow margin | 14.5% | 20.2% |
| Earnings per share (diluted) | $27.85 | -$0.35 |
| Cash | $529.8M | $474M |
| Debt | $1.2B | n/a |
| Price to earnings | 13.7 | n/a |
| Market value | $10.2B | $11.2B |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #194 of 451 · Industrials | #299 of 451 · Industrials |
Over the years
Questions about Bio-Rad Laboratories and 10x Genomics
Which is bigger by revenue, Bio-Rad Laboratories or 10x Genomics?
Bio-Rad Laboratories is bigger by revenue: $2.6B in fiscal 2025, against $642.8M for 10x Genomics in fiscal 2025.
Which keeps more of its revenue as profit, Bio-Rad Laboratories or 10x Genomics?
Bio-Rad Laboratories had a net margin of 29.4% in fiscal 2025; 10x Genomics had -6.8% in fiscal 2025.
Which grew revenue faster, Bio-Rad Laboratories or 10x Genomics?
In their latest fiscal years revenue changed by +0.7% at Bio-Rad Laboratories and +5.2% at 10x Genomics.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.